Analyst Research

Report Title Price
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.
Provider: New Constructs, LLC
Provider: S&P Capital IQ – STARS Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Alexion Pharmaceuticals Inc Issues FY 2013 Guidance Above Analysts' Estimates

Thursday, 14 Feb 2013 06:29am EST 

Alexion Pharmaceuticals Inc announced that for fiscal 2013, it expects worldwide net product sales to be within a range of $1.490 billion to $1.505 billion and non-GAAP earnings per share (EPS) in the range of $2.82 to $2.92. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $1.485 billion and EPS of $2.81 for fiscal 2013. 

Company Quote

-5.2 -3.11%
12:33pm EDT